Bio-Thera’s Biosimilar BAT1806 Passes NMPA Review, Targets Roche’s Actemra
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that its biosimilar drug BAT1806, modeled after...
Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...
AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab
China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole...
China’s NHC Releases Second National Drug Use Monitoring List
China’s National Health Commission (NHC) has released the second national drug use monitoring list, covering...
Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion
China-based X-ray imaging core component supplier Suzhou Powersite Electric Co., Ltd has reportedly raised hundreds...
Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion
Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance...
CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers
CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor...
Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...
Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
Bristol-Myers Squibb’s Opdivo Secures Two New Approvals for Esophageal Cancer in China
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has received two new indication approvals in...
Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving another indication approval from China’s...
Agilis Robotics Completes Successful Animal Testing for Surgical Robot
Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing...
CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China
China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...
Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China
China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have...
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...
Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines
Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly...
ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline
ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions”...
Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder
China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...
WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference
China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...